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Congress and the President
Scott Davison*
I. INTRODUCTION
"COMMUNITY, IDENTITY, STABILITY." This is the motto of
World State, the global government envisioned by Aldous Huxley in
Brave New World.1 These words are imprinted on a shield outside the
"Central London Hatchery and Condition Centre," where the
government controls the birth of all new humans by creating scores of
clones. 2  Huxley's "brave new world" is a well-oiled machine
controlled by one omniscient government that maintains the happiness
of all its citizens. The same cannot be said of the United States.
Instead, we have large government agencies that must react to
congressional law and executive policy. In the field of biomedical
research, agency decision making can cripple an industry and swamp
promising new therapies in red tape. This is the current state of events
for embryonic stem-cell research-a controversial new discovery in
biomedical science that promises phenomenal results. Scientists hope
that research with embryonic stem-cells will produce treatments and
cures for debilitating diseases such as diabetes, Parkinson's, and
Alzheimer's. The medical community continues to pursue this dream
with passionate fervor, pressing for every possibility and potential
avenue of biological research in an attempt to knock out some of the
most deadly and damaging diseases known to man.
* J.D. Candidate, 2003, Pepperdine University School of Law; B.S.,
Biomedical Science, Texas A&M University.
1. ALDOUS HUXLEY, BRAVE NEW WORLD 1 (Harper Collins Publishers 1998)
(1946).
2. Id. at 3.
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Stem-cells were first discovered in 1998 by University of
Wisconsin researcher James Thomson. An embryonic stem-cell is a
cell that is derived from the inner cell mass of a human embryo and has
the potential to develop into all or nearly all of the tissues of the body-
such as brain cells, muscle cells, nerve cells, or cardiac cells.4 With the
potential to develop into so many types of cells, scientists call them
"pluripotential" embryonic stem-cells.5 In the laboratory, these cells
divide indefinitely on a petri dish and still maintain their pluripotential
characteristics, 6 thus making them ideal subjects for all types of
biomedical research. Embryonic stem-cells in particular are the most
attractive to scientists, because adult stem-cells lack the same degree of
pluripotentiality and may have limited therapeutic capabilities when
compared to embryonic stem-cells.7 Scientists believe that stem-cell
research, because of the characteristics of stem-cells, could lead to
therapies to treat over 128 million diseased Americans. 8 Treatments for
heart disease, diabetes, Parkinson's, and even regeneration of the
nervous system in paralysis patients or brain tissue in stroke victims are
all within the breadth of stem-cell research. 9 Studies have shown stem-
cells capable of repairing nerve damage and reversing the symptoms of
diabetes.10 Researchers at Harvard Medical School announced in
January 2002 that embryonic stem-cells may alleviate the symptoms of
Parkinson's patients after embryonic stem-cells injected into mice
spontaneously converted to the nervous cell responsible for producing
dopamine, a crucial chemical missing in patients afflicted with the
3. James A. Thomson, et al., Embryonic Stem Cell Lines Derived from Human
Blastocysts, 282 SCIENCE 1145, 1145 (1998).
4. See Gabriel S. Gross, Federally Funding Embryonic Stem Cell Research: An
Administrative Analysis, 2000 Wis. L. REv. 855, 855 (2000).
5. Press Release, The White House, Fact Sheet: Embryonic Stem Cell
Research, available at http://www.whitehouse.gov/news/releases/2001/08/
20010809-1.html (August 9, 2001) [hereinafter Fact Sheet].
6. Gross, supra note 4, at 856.
7. Press Release, supra note 5; see also Christine Kirk, Research Guidelines:
NIH Issues Guidelines for Federally Funded Stem Cell Research. 28 J.L. MED. &
ETHICS 411,412 (2000).
8. Fact Sheet, supra note 5.
9. Gross, supra note 4, at 856.
10. Rachel K. Sobel, Miracle Cells? Maybe More Research Dollars, More
Ethical Quandries, US NEWS & WORLD REP., Sept. 4, 2000, at 22.
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debilitating brain disease." Another recent study at Duke University
found that stem-cell transplants in infants with severe combined
immunodeficiency are ninety-five percent successful in curing that
condition.12 The potential for embryonic stem-cells to cure a plethora
of diseases has brought these cells great significance in the scientific
community, but their source has brought them significant attention
from the political community as well.
Unfortunately for many researchers, federal funding of embryonic
stem-cell research is in the hands of the federal government and is now
the subject of an intense public debate. The primary point of contention
is the source of the embryonic stem-cells and the process of extracting
them. The only method of obtaining an embryonic stem-cell is to
destroy a human embryo, which raises paramount ethical and moral
concerns for scientists, policymakers, and society as a whole.' 3 The
embryo, a medical term for a fertilized egg, is considered by some to be
a person, while others contend that the embryo has not achieved
personhood yet. Religious organizations, "anti-abortion groups, bio-
ethicists, scientists, government officials, members of Congress, and
patient advocate groups" all oppose the destruction of the embryo for
research purposes. 14 The pro-life movement in particular believes that
because an embryo is a human being, destroying the embryo amounts
11. Rats with Parkinson's Helped by Stem Cells, THE GLOBE AND MAIL, Jan.
15, 2002, at R8.
12. Thomas H Maugh, II, Science File IN BRIEF: Stem Cell Treatment for
SCID Infants a Success, L.A. TIMES, Jan. 28, 2002, at A 10.
13. Fact Sheet, supra note 5. The process of extracting stem-cells from an
embryo requires the destruction of that embryo. Gross, supra note 4, at 856.
Scientifically speaking, the blastocyst, or outer core of the embryo, is separated
from the inner mass of cells, where stem-cells are located. Id. at 857. It must be
noted, however, that embryonic stem-cells are not the only stem-cells available.
Several other sources, including adult bone marrow and the umbilical cord of a
newborn baby are latent with stem-cells. In fact, scientists have used these stem-
cells in biomedical research since the initial discovery in 1998. However, many
researchers assert that embryonic stem-cells are more beneficial to research, and
that preventing use of embryonic stem-cells will further impede the progress for the
great cures to diseases that stem-cell research promises. New research, however,
has called some of these claims into doubt. Infra note 109.
14. Nelle S. Paegel, Use of Stem Cells in Biotechnological Research, 22
WHITTIER L. REV. 1183, 1186 (2001).
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to the taking of human life.15  Proponents of embryonic stem-cell
research contend that the embryos are not yet human beings, but
"potential" human beings, and thus, deserve a heightened degree of
respect, but nothing more.' 6  In addition, proponents argue that the
embryos used for research purposes are "leftover" embryos from in-
vitro fertilization procedures that would otherwise be destroyed or
frozen indefinitely. 17 If the embryos are going to be destroyed anyway,
they argue, why not use them for noble purposes such as stem-cell
research? 18  Of course, if the embryo really is a human life, the
destruction of that life is no doubt called into question, no matter how
great the reasons for destroying that embryo may be. Thus, with any
great ethical debate, the nation's leaders are quick to weigh in, and any
government policy dealing with the controversy, such as federal
funding of research involving embryonic stem-cells, is necessarily the
subject of immediate concern.
The current debate in the federal government focuses almost
entirely on the use of federal funding for embryonic stem-cell research.
Hence, the private funding of embryonic stem-cell research is
unaffected (at least not directly) by any decision that has been, or will
be made, involving federal funding. 19  Additionally, although a
complete ban on embryonic stem-cell research would impact the
private sector, it is doubtful that either President Bush or Congress will
15. Id. at 1199.
16. Gross, supra note 4, at 857.
17. See id. During the in-vitro fertilization process, a popular fertility
treatment, scientists combine a couple's sperm and egg to create several different
embryos. One embryo is then placed in the female's uterus until the embryo
implants and begins to develop. Once this occurs, the remaining embryos are
temporarily frozen for storage, should the couple decide to undergo the process
again. However, the in-vitro fertilization clinics eventually destroy the unneeded
embryos, a source of controversy in and of itself.
18. See generally id; see also Paegel, supra note 14, at 1220.
19. Private companies, such as Geron Corporation, are at the forefront of
embryonic stem-cell research, and necessarily in competition with any government
effort to fund such research. Most corporations, however, support federal funding
of embryonic stem-cell research, since they are also applying for federal grant
money to conduct the research.
22-2
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consider taking the matter to that degree.20 Hence, the controversy
revolves around whether or not taxpayer dollars should be used to
promote embryonic stem-cell research projects. Proponents of
embryonic stem-cell research claim that federal funding is essential to
jumpstart research in this particular field, and without it, life-saving
therapies and drugs might be delayed for years. Opponents of federal
funding argue that taxpayers should not have their money spent on
something that they consider immoral. The National Institutes of
Health ("NIH"), an administrative agency within the Department of
Health and Human Services, oversees federal funding for stem-cell
research. 21  The NIH interprets Congressional law, complies with
executive orders from the President and creates standards for
organizations to obtain federal funding for many types of biomedical
research.22
After a flurry of debate in 2001 over the use of federal funding for
embryonic stem-cell research, President Bush engineered a careful
compromise that attempted to promote embryonic stem-cell research
while respecting the status of the embryo, which he considers to be a
human life.23 The President then charged the NIH with the task of
implementing the compromise and developing the rules and guidelines
used to allocate federal grant money for embryonic stem-cell
research.24 The NIH developed these standards in late 2001, but it
20. The consequences of a complete ban on embryonic stem-cell research
create fears of a national "brain drain" that would pull prominent researchers and
cutting-edge scientific minds from the United States to countries where more
permissive biomedical research is available. David Akin, Genetics on the Run,
GLOBE & MAIL, reprinted Feb. 6, 2002, at A15. Germany recently struggled with
this argument in early 2002 when their Parliament voted to restrict embryonic
stem-cell research. Infra note 99. In addition, Great Britain recently passed
measures guaranteeing the right of scientists to conduct research on embryos, the
complete opposite of public policy efforts in the United States. Vanessa Fuhrmans
& William Boston, German Parliament Votes 'Yes' on Import of Stem-Cell Lines,
WALL ST. J., Jan. 31, 2002, at B10.
21. Gross, supra note 4, at 858-59.
22. Id.
23. Press Release, George W. Bush, Remarks by the President on Stem Cell
Research, available at http://www.whitehouse.gov/news/releases/2001/08/
20010809-2.html (August 9, 2001) [hereinafter Bush].
24. Id.
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remains to be seen whether Congress will exercise its own power and
mandate new rules for embryonic stem-cell research; trumping Bush's
plan and sending the NIH back to the drawing board once more.
This comment will discuss the administrative history of NIH policy
on embryonic stem-cell research and how the President and Congress
jointly influence that policy. Part II discusses the history of stem-cell
research and government funding, including the most recent
developments up to and including the Bush Compromise. In Part III,
the impact of the Bush Compromise on NIH policy will be analyzed,
along with Congressional reaction and the effect on NIH rulemaking
and interpretation. Finally, Part IV will conclude with a discussion of
the future of embryonic stem-cell research, NIH policy and the
influence of science over this complex administrative issue.
II. HISTORY OF STEM-CELL RESEARCH AND "THE BUSH COMPROMISE"
Before scientists had even discovered stem-cells, let alone their
incredible potential, the law had already spoken to the issue of
biomedical research on embryos and fetal tissue. President Reagan
banned federal funding for any research using fetal tissue at the
beginning of his administration, arguing that permitting such
controversial experimentation would encourage abortion and indirectly
implicate the taxpayers for the increase.25 President George Bush
maintained that ban during his four years in office, 26 preserving the pro-
life view that any experimentation on a fetus or embryo is equivalent to
experimentation on a human being. However, the political climate
would soon change, bringing significant implications for the
biomedical research community. On President Clinton's first day in
office in 1993, the ban on fetal tissue research was lifted by a
controversial executive order that paved the way for future federal
funding for research projects involving embryos and other forms of
fetal life and ignited debate over the federal funding of any research
that might use fetal tissue.2 7 Congress reacted in 1995 by attaching a
25. Paegel, supra note 14, at 1199.
26. Id.
27. Id. at 1188.
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rider to an appropriations bill that prevented federal funds from being
used for any research in which a human embryo is destroyed or
subjected to risk of injury.28 Since 1996, similar language prohibiting
the use of federal funds for embryo research has appeared within the
federal budget.2 9
Sensing that the conflict required a greater understanding than
policymakers were accustomed to, Clinton created the National
Bioethics Advisory Commission ("NBAC") in 1995.30 The President
asked the NBAC to research and make recommendations on
controversial issues, including embryonic stem-cell research. 31 The
NBAC was made up of researchers, bioethicists, and public
policymakers-all with different perspectives on the controversial
issues.32 In 1999, the NBAC released a report entitled "Ethical
Issues in Human Stem-Cell Research," which recommended federal
funding for embryonic stem-cell research on a broad scale, despite
moral and ethical objections. 33  Specifically, the NBAC
28. Consolidated Appropriations Act of 2000, Pub. L. No. 106-113, § 510(a),
113 Stat. 1501, 1501A-275 (1999). The relevant portion states:
None of the funds made available in this Act may be used
for-
(1) the creation of a human embryo or embryos for
research purposes; or
(2) research in which a human embryo or embryos are
destroyed, discarded, or knowingly subjected to risk of injury
or death greater than that allowed for research on fetuses in
utero under 45 CFR 46.208(a)(2) and section 498(b) of the
Public Health Service Act (42 USC 289g(b)).
Id.
29. Sharon M. Parker, Bringing the "Gospel of Life" to American
Jurisprudence: A Religious, Ethical, and Philosophical Critique of Federal
Funding for Embryonic Stem Cell Research, 17 CONTEMP. HEALTH L. & POL'Y
771, 776-77 (2001).
30. Nat'l Bioethics Advisory Comm'n, Ethical Issues in Human Stem Cell




33. Id. at 70, available at http://www.georgetown.edu/research/nrcbUnbac/
stemcell.pdf.
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recommended that the NIH permit direct federal funding for the
harvesting of stem cells from human embryos.3 4
Based upon the NBAC recommendation, the NIH then announced
in August 2000, that federal funds would be granted for research on
embryonic stem-cells. 35 Then NIH Director, Harold Varmus, and then
Commissioner of the Department of Health and Human Services
("DHHS"), Donna Shalala, requested a legal opinion in 1998 on the
applicability of the Congressional research ban to embryonic stem-cell
research.36  Two months later, the DHHS concluded that the
congressional ban on human embryo research did not apply to
embryonic stem-cell research.37 The basis for this interpretation rests
on the idea that stem-cells do not comprise a full embryo under the
statutory definition 38 because they "do not have the capacity to develop
into a human being." 39 Stem-cells were therefore not subject to the
research ban, as long as federal funds did not pay for the actual physical
extraction of the stem-cells from the embryo.40 Congress voiced strong
opposition to the NIH interpretation and guidelines, alleging that the
DHHS interpretation violated the will of Congress. Some members of
Congress reasserted the terms of the appropriations rider, emphasizing
34. Id.
35. Paegel, supra note 14, at 1183.
36. Id., at 1198.
37. Id., at 1184.
38. The definition states:
For purposes of this section, the term "human embryo or
embryos" includes any organism, not protected as a human
subject under 45 CFR 46 as of the date of the enactment of
this Act, that is derived by fertilization, parthenogenesis,
cloning, or any other means from one or more human
gametes or human diploid cells.
Consolidated Appropriations Act of 2000, Pub. L. No. 106-113, § 510(b), 113 Stat.
1501, 1501A-275 (1999).
39. Elliot Abram et al., On Human Embryos and Medical Research: An Appeal
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that "Congress .. .doesn't want to have anything to do with the
termination of an embryo.",4 1
A legal challenge to the NIH interpretation and guidelines to permit
research in embryonic stem-cells would be governed by the standard set
forth by the Supreme Court in Chevron v. Natural Resources Defense
Council.42 Chevron stands for the proposition that when Congress is
silent on a particular issue, deference to the appropriate administrative
agency is the proper course of action.43 According to at least one legal
mind, any challenge to the NIH interpretation would fail under the
Chevron standard and other Supreme Court precedent.44 If Chevron is
applied, the initial conclusion is to validate the NIH interpretation based
on a presumption that Congress is silent as to the particular issue of
federal funding for embryonic stem-cell research. However, if the NIH
policy to permit research resulting from the destruction of an embryo
was interpreted to indirectly cause the destruction of an embryo, the
Court could potentially strike down the agency interpretation, a major
step back for researchers in favor of embryonic stem-cell research and
the potential benefits of federal funding in this arena.
The debate over embryonic stem-cell research heated up with the
inauguration of President George W. Bush in January 2001. Paralleling
the Clinton style, Bush re-instituted the previous moratorium on federal
funding of embryonic research within days of taking office, 45 thus
following in the footsteps of his father and other Republican
predecessors. Hence, the new NIH guidelines allowing federal funding
were effectively halted before a dime of federal money was handed
out.46 The moratorium sparked immediate debate, and as results from
private research efforts began to highlight the enormous potential of
41. Nicholas Wade, Government Proposes Regulations for Embryo Cell
Research, N.Y. TIMES, Dec. 2, 1999, at A24 (quoting Congressman Jay Dickey).
42. Chevron v. Nat'l Res. Def. Council, 467 U.S. 837 (1984).
43. Id.
44. Gross, supra note 4, at 881.
45. Stem Cell Plaintiffs Seek Summary Judgment, Want NIH Guidelines
Restored, 44 THE BLUE SHEET 29, July 18, 2001.
46. Id.
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stem-cells,47 the pressure on Bush to permit federal funding grew.48
During the summer of 2001, the stem-cell debate was front-page news,
and to-date, the most morally significant issue that President Bush
confronted since his inauguration. Many in the press and political
circles considered the stem-cell issue the first test of the new
President.49
After months of careful political maneuvering and discussion,
President Bush spoke to the nation in a live television address on
August 9, 2001 and announced a bold solution. 50 Thereafter known as
"the Bush Compromise," Bush approved federal funding for embryonic
stem-cell research on existing stem-cell lines, but also prohibited
funding for any additional stem-cell lines derived after the date of the
speech.51 The Bush Compromise captured the very essence of the
word-permitting federal funding for the enormously promising
embryonic stem-cell research and respecting the value of human life,
even in the embryonic form, that many Americans believe in. Bush
stated that over sixty existing stem-cell lines were available for research
47. Paegel, supra note 14, at 1188-93. Congress has yet to enact a complete
ban on embryonic stem-cell research by any individual or corporation, so efforts by
the private sector have continued since the initial discovery of stem cells in 1998.
Id. The economic potential for stem-cell research is so great that several companies
are currently in litigation over the rights to patents on stem-cells and the methods of
research. Id. at 1196-98. Proponents of embryonic stem-cell research believe that
federal funding will provide such an influx of research dollars that the conflicts in
the private sector will soon be moot. However, even the NIH has had to negotiate
with the patent owners of stem-cells for the rights to distribute those cell lines for
federal research dollars. See infra note 57.
48. Paegel, supra note 14, at 1200-01.
49. The argument that federal funding of embryonic stem-cells was a
presidential "test" was asserted both before and immediately after the
announcement of the Bush Compromise (see infra Section II), but in light of the
tragedies of September 1 th, it will doubtfully be remembered as such. However,
immediately after the Bush Compromise, most believed that the solution hammered
out by the President earned him a passing grade. No one could fathom how much
Bush's leadership would really be tested in the coming months.
50. Bush, supra note 23.
51. Id. Specifically, the President permitted research on sixty existing stem-
cell lines where the destruction of the embryo had already taken place. Id. As
Bush put it, "I have concluded that we should allow federal funds to be used for
research on these existing stem-cell lines, where the life and death decision has
already been made." Id. (emphasis added).
22-2
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at the time of his decision.52 In addition, Bush created a President's
Council on Bioethics ("Council") "to monitor stem-cell research, to
recommend appropriate guidelines and regulations, and to consider all
of the medical and ethical ramifications of biomedical innovation." 53
Bush appointed prominent biomedical ethicist Leon Kass to lead the
Council, and promised to include scientists, doctors, lawyers, and
theologians.54 In contrast to the NBAC, the Council would no doubt
have a somewhat more conservative slant.55 However, despite the
clever solution penned out by the President, the debate did not end.
While the President charged the NIH to implement his new guidelines,
Congress continued to devise its own solution, suggesting more lenient
regulations of embryonic stem-cell research that allowed the
destruction of additional embryos "leftover" from in vitro
52. Id. The NIH provided this number to the President after an extensive,
worldwide search in the months preceding his announcement. Bush requested the
NIH to conduct the search in June, indicating that Bush had most likely already
developed the compromise plan that he announced in August, and initiated the NIH
search in an effort to legitimize his decision. In fact, the NIH returned to Bush with
sixty-four potential embryonic stem-cell lines. See infra note 72.
53. Id.
54. Fact Sheet, supra note 5.
55. Id. In a more recent development, the President announced the
membership of the eighteen-member Council in January 2002. They include:
Elizabeth Blackburn, University of California, San Francisco; Stephen Carter, Yale
Law School; Rebecca Dresser, Washington University School of Law; Daniel
Foster, University of Texas Southwestern Medical School; Francis Fukuyama,
Johns Hopkins University; Michael Gazzaniga, Dartmouth College; Robert George,
Princeton University; Alfonso Gomez-Lobo, Georgetown University; Mary Ann
Glendon, Harvard University; William Hurlbut, Stanford University; Charles
Krauthammer, The Washington Post; William May, Southern Methodist
University; Paul McHugh, Johns Hopkins University School of Medicine; Gilbert
Meilaender, Valparaiso University; Janet Rowley, University of Chicago; Michael
Sandel, Harvard University; and James Wilson, University of California, Los
Angeles. Patients Seek Representation on Bush Bioethics Council, 34 WASH.
DRUG LETTER, Jan. 28, 2002, available at 2002 WL 8399913. Fourteen of the
eighteen members are considered conservatives. Id. Ironically, the Council
announced in late January 2002 that discussion at its first meeting would not
involve embryonic stem-cell research, but human cloning. Seth Goldman,
President's Council on Bioethics to Examine Human Cloning Issues, U-WIRE,
January 28, 2002, available at 2002 WL 8295843. The public policy debate on
embryonic stem-cell research, in a period of less than six months, has apparently
given way to the next scientific push, therapeutic cloning of embryos. Id. The
cloning debate will be discussed more thoroughly in Section IV, infra.
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fertilization.5 6 This congressional push reflected an unusual alliance of
abortion opponents with proponents, all in support of federal funding
for embryonic stem-cell research.57 The private sector, somewhat un-
phased by the melee in Washington, continued to fund projects with
embryonic stem-cells, subject only to public criticism and pressure
from embryonic stem-cell research opponents, who claimed that the
bottom line is more important to these companies than the embryo
itself.58
III. THE IMPACT OF THE BUSH COMPROMISE
A. Effect on the National Institutes of Health
Weeks after President Bush's announcement, the NIH released a
plan for federal funding of research using specified existing human
embryonic stem-cells.5 9 The initial guidelines set forth by the NIH
provided for federal funding of embryonic stem-cell research as long
as: (1) "the derivation process was initiated prior to 9:00p.m. Eastern
Daylight Time on August 9, 2001" (the date of President Bush's
announcement), (2) the stem-cells are derived from an embryo that was
created for reproductive purposes and was no longer needed, (3)
donation of the embryo was obtained through informed consent of the
biological parents, and (4) that donation must not have involved
financial inducements. 60  These requirements parallel those of the
original NIH guidelines for embryonic stem-cell research announced
almost one year prior to the Bush Compromise, with the addition of
56. Daniel S. Greenberg, Bush Stem-Cell Plans Draw Skepticism in Senate,
358 THE LANCET 849, Sept. 14, 2001, available at 2001 WL 10159575.
57. Id.
58. Several companies have recently bowed to this pressure. After announcing
in July, 2001 that it would begin cloning human embryos for the sole purpose of
harvesting stem-cells (something President Bush sternly criticized), the Jones
Institute for Reproductive Medicine at Eastern Virginia Medical School backed off
its efforts to pursue human embryonic cloning, announcing that it would stop the
practice entirely. Lab Will End Stem-Cell Policy, ORLANDO SENTTINEL, Jan. 18,
2002, at A15, available at 2002 WL 3025243.
59. Press Release, National Institutes of Health, National Institutes of Health
(NIH) Update on Existing Human Embryonic Stem Cells (Aug. 27, 2001), at
http://www.nih.gov/news/stemcell/082701list.htm [hereinafter NIH Update].
60. Id.
22-2
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President Bush's restriction that funding take place on a restricted list
of previously derived stem-cell lines. In early November 2001, the
NIH released a notice of withdrawal of the prior stem-cell regulations
originally released a little over one year earlier, thus completing the
agency's 180-degree policy turn.61  Another minor change to the
regulations involves the informed consent requirement, which is now a
general requirement left to agency interpretation. 62 Previously, NIH
regulations required specific and explicit informed consent.63 The
Council is also replacing the NIH Ethics Review Panel, a body similar
to an institutional review board that reviewed and approved NIH
programs. The Council, therefore, lacks oversight powers over NIH
policy which the Ethics Review Panel once held, thereby giving the
agency more direct control over rulemaking. This may spark fear of
unchecked agency rulemaking, but given the public interest in stem-cell
research, it is doubtful that agency officials at the NIH will escape the
scrutiny and accountability of the press or the public on such a
controversial issue. The NIH also announced the creation of a Human
Embryonic Stem-Cell Registry ("Registry") to list the stem-cells that
meet the eligibility criteria.64 This Registry was finally published in
November 2001, and currently lists eleven research entities where
embryonic stem-cells may be obtained, with a total of seventy-two
separate embryonic stem-cell lines. 65  Although the events of
61. Press Release, National Institutes of Health, NIH Guide: Notice of
Withdrawal of NIH Guidelines for Research Using Pluripotent Embryonic Stem
Cells (Nov. 7, 2001), at http://grants.nih.gov/grants/guide/notice-files/NOT-OD-
02-007.html.
62. Thomas H. Murray, Hard Cell: The Ethics and Politics of Stem Cell
Research, 12 AM. PROSPECT, Oct. 1, 2001, at A7, available at 2001 WL 7681221.
63. Id.
64. NIH Update, supra note 59.
65. National Institutes of Health, National Institutes of Health Human
Embryonic Stem Cell Registry, at http://escr.nih.gov/ (last visited Feb. 5, 2002).
The Registry also published more formal guidelines for embryonic stem-cell lines
to qualify for federally-funded research. They state that federal funds may be used
for research on existing human embryonic stem-cell lines:
[A]s long as prior to his announcement (1) the
derivation process (which commences with the removal of
the inner cell mass from the blastocyst) had already been
initiated and (2) the embryo from which the stem-cell line
was derived no longer had the possibility of development as
a human being.
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September 1 1th delayed NIH plans for about a month, agency officials
continued to develop drafting proposal sheets and applications for grant
proposals in preparation for the publication of the Registry and the
announcement of the first available grants for embryonic stem-cell
research. 6 6  The NIH hopes that effort will hasten the process of
processing applications and approving grants. Also, in August 2001,
the NIH announced an agreement with the Wisconsin Alumni Research
Foundation ("WARF") for licenses to use the patents on WARF's
embryonic stem-cells. 67 DHHS Secretary Tommy Thompson testified
that the NIH reached a deal with WARF for unrestricted access to five
patented cell lines owned by WARF. 68 However, despite this licensing
agreement, the NIH is limited to facilitating the transfer of cells from
the owners to the researchers and has no direct control over the
embryonic stem-cell lines.69 Funding for embryonic stem-cell research
is available through a variety of methods devised by the NIH including:
grants, contractual agreements, cooperative agreements, and
supplements to existing grants.7 0
Id. The additional criteria required that:
[T]he stem-cells must have been derived from an embryo
that was created for reproductive purposes[;] the embryo was
no longer needed for these purposes[] informed consent
must have been obtained for the donation of the embryo[;
[and] [n]o financial inducements were provided for donation
of the embryo.
Id.
66. Stem Cell Research Guidelines, 44 THE BLUE SHEET 41, Oct. 10, 2001, at
p. 14 [hereinafter Research Guidelines].
67. NIH Update, supra note 59.
68. Greenberg, supra note 56. The additional companies with existing
embryonic stem-cell lines identified by the NIH include: BresaGen, Inc., Cythera,
Inc., Goteburg University (Sweden), Karolinska Institute (Sweden), Monash
University (Australia), National Center for Biological Sciences (India), Reliance
Life Sciences (India), Technion-Israel Institute of Technology (Israel), University
of California at San Francisco, and Wisconsin Alumni Research Foundation.
Embryonic Stem Cells: Health Officials Identify 10 Stem Cell Labs Eligible For
U.S. Research Funds, BLOOD WEEKLY, Sept. 13, 2001, available at 2001 WL
7493882.
69. NIH Update, supra note 59.
70. Availability of Stem Cells for Research: Hearing Before the House
Judiciary Committee, 106th Cong. (Oct. 31, 2001) (statement of Wendy Baldwin,
Ph.D).
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B. Critics of the Bush Compromise
However, implementation of the Bush Compromise by the NIH has
not come without criticism. From the moments immediately after
Bush's speech, critics began to question the estimated sixty pre-existing
embryonic stem-cell lines purported to be in existence by the
President. 7' The NIH, which initially made the claim to President Bush
in a private report commissioned by the President over a month before
his August 2001 announcement, was forced to defend its' claim that
such a significant number of stem-cell lines existed throughout the
world, when most biomedical researchers were aware of about two
dozen.72  After significant criticism, DHHS Secretary Tommy
Thompson made several public statements and testified before
Congress about the viability of the embryonic stem-cell lines identified
by the NIH, finally resolving the issue and verifying that as of the
announcement of The Bush Compromise, sixty-four embryonic stem-
cell lines existed and were available for use by researchers.73
71. From a scientific standpoint, the number of stem-cell lines is important for
several reasons. Cell lines react as differently to biomedical research as human
beings do, so having a diverse bank of stem-cell lines with which to test therapies
and new drugs, for example, is particularly advantageous. The more diverse the
stem-cell lines are, the more tailored a particular therapy will be for the patient, and
thus, more effective. In addition, most embryonic stem-cell lines are currently
derived from a remarkably similar population base-the average Caucasian male.
Thus, without a significant number of cell lines, therapies of the future will be
useful to the same population on which the research was done. However, this
conclusion may be presumptuous, simply because most scientists advancing these
arguments are passionate opponents of government restrictions on embryonic stem-
cell research, and may have other motives.
72. Television Interview by Katie Couric with Tommy Thompson, DHHS
Secretary, on NBC News: Today (Sept. 7, 2001), available at 2001 WL 26427092
[hereinafter Interview].
73. Interview, supra note 72. The NIH Stem Cell Registry currently lists
seventy-two cell lines available for research. Supra note 51. The difference in
numbers is primarily the result of recent scientific developments of ES cell lines
that may not have been viable at the time of the Bush Compromise. These
additional embryonic stem-cell lines were not extracted from the embryo after the
deadline, in violation of Bush's ultimatum, but at the time they were probably in
the initial stages of development and not reliable enough to be counted as an
official NIH embryonic stem-cell line.
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Despite this promise, and the wide availability of embryonic stem-
cell lines, researchers were asked by the NIH to halt any research using
embryonic stem-cells until new rules were formulated and finalized in
accordance with the Bush plan.74 The timeline is longer than most
imagined, but is typical of government research grant programs.75
Nevertheless, researchers awaiting federal funding will face a lengthy
application and approval process, meaning federal dollars would not
have been available for embryonic stem-cell research until late 2002.76
This waiting period is detrimental to The Bush Compromise and the
new NIH Guidelines for one main reason-time. The regulatory
history of stem-cell research has borne only one consistency throughout
its four year existence: the more time required to make a decision, the
more often the decision will change. Should NIH policy undergo
another overhaul, even more time will be needed to implement the next
solution-ultimately delaying any federal funding for several years.
Despite the dissatisfaction of many groups with the Bush Compromise,
delay may be too great to risk another major policy change.
C. Fate of the Bush Compromise: Will Congress Take Control?
Congressional action is the biggest threat to the Bush Compromise.
Even before the Bush Compromise, members of Congress repeatedly
made their opinions clear, that the benefits of embryonic stem-cell
research would certainly outweigh any moral restraints. 77 Once Bush
established guidelines for the NIH on embryonic stem-cell research,
Congress raced to implement its own solution in a classic separation of
powers tug-of-war.78 With the medical potential to cure many diseases
of the growing elderly population, and with the predominantly senior
74. NIH Update, supra note 59.
75. Of course, this delay pertains solely to those researchers seeking federal
funding for their research. The private sector remains unscathed by the recent
developments, and has even progressed to the next ethical boundary in their pursuit
of the most cost-effective and beneficial therapies-biomedical research using
cloned human embryos. George W. Bush, Address, supra note 23. See Section IV,
infra, for a complete discussion of human embryonic cloning.
76. Interview, supra note 72.
77. Specter Stem Cell Bill Support Likely Lost to Bush Compromise
Contentment, 44 THE BLUE SHEET 33, Aug. 15, 2001 [hereinafter Specter Bill].
78. Id. NIH Embryonic/Adult Stem Cell Comparative Study Requested in
DeGette Bill. 44 THE BLUE SHEET 33, Aug. 15, 2001 [hereinafter Degette Bill].
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membership of both the House and Senate, it is no wonder that
Congress favors embryonic stem-cell research so strongly. Most
recently, a Senate subcommittee approved a bill providing for federal
funding of embryonic stem-cell research that permits an exception to
the restrictions of the Bush Compromise. 79 Ironically, the proposed
legislation gives the President decision-making power to grant further
development of embryonic stem-cell lines,80 a strategic move most
likely intended to put pressure on the President, rather than Congress,
should current embryonic stem-cell research opportunities prove
inadequate. The legislation specifically permits the President to allow
the destruction of more embryos for research than those already
specified, but it requires that the new stem-cell lines originate from
embryos that would otherwise be destroyed.8 ' In the typical
Congressional effort to appease wary bioethicists, the law would
require stringent informed consent by the donors.8 2  A recent
amendment to the bill would permit couples to donate embryos for
research purposes if the embryo would otherwise be destroyed8 3
All along, the White House has maintained its position that the
Bush Compromise will succeed, and in October 2001 supported the
House version of that bill, which made no such changes to the original
Bush Compromise. 4 Indeed, DHHS Secretary Tommy Thompson
maintained the Bush Administration's decision not to reconsider the
August 9, 2001 deadline for embryonic stem-cell lines to be derived,
invoking the threat of a presidential veto on any legislation contrary to
Bush's new guidelines. 85 But Senator Arlen Specter, the sponsor of the
more expansive Senate bill, claims he has the support of almost
seventy-five Senators, 86 a number that would override a presidential
veto should the issue ever arise.8 7 However, in early November 2001




83. Stem Cell Pool May Grow, THE GRAND RAPIDS PRESS, Nov. 1, 2001, at
A2, available at 2001 WL 29517018.
84. Specter Bill, supra note 74.
85. Greenberg, supra note 56.
86. Id.
87. Id.
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the Senate backed off its position to ease the restrictions for embryonic
stem-cell research after the insinuation of a Bush veto of the measure.
88
Another House resolution being pushed would direct the NIH to
conduct a study comparing embryonic stem-cell research to adult stem-
cell research,89 presumably in an attempt to make the issues clearer in
determining the need for embryonic stem-cell research over basic stem-
cell research as it was originally developed. 90
Meanwhile, the term of the National Bioethics Advisory Council
quietly expired in the Fall of 2001.91 The final report of the NBAC,
released in August 2001, endorsed funding of embryonic stem-cell
research with minimal restrictions and a few ethical protections.
92
Clearly opposed to the President's objectives in this arena, it is little
wonder that the NBAC will fold under the newly formed Council on
Bioethics.
IV. IMPACT OF THE BUSH COMPROMISE ON THE NIH
A. NIH at a Loss
The NIH has faced a loss of decision-making and interpretive
power since the Bush Compromise, mostly as a result of the heightened
political climate surrounding embryonic stem-cell research. As long as
88. Alan Fram, Facing Veto Threat, Senators Drop Effort to Ease Bush
Restrictions on Stem Cell Research, ASSOCIATED PRESS NEWSWIRES, Nov. 2, 2001.
89. Degette Bill, supra note 75.
90. See infra Section IV for more recent developments in the distinction
between adult and embryonic stem-cells.
91. Research Guidelines, supra note 66. While little media attention was
given to the expiration of the NBAC, the move was no doubt politically motivated.
In its brief tenure, the NBAC released several reports favoring liberal policies, most
significantly the 2000 report promoting embryonic stem cell research. Paegel,
supra note 14, at 1183. This report led to the crucial "reinterpretation" of the
Congressional law that prohibited federal funding of any research where an embryo
would be harmed or destroyed. It was no doubt assumed that the creation of the
President's Council on Bioethics marked the end of the NBAC from a political
standpoint. Conveniently for President Bush, the NBAC commission expired
before any action was needed.
92. Nat'l Bioethics Advisory Comm'n, supra note 30.
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government policy pushes the boundaries of the public's morals and
ethics, no administrative agency can lie quietly by and engage in
rulemaking and interpretation without the careful scrutiny from the
President, Congress, and the public. The Bush Compromise effectively
closed the loophole in regulation of federal funding for embryonic
stem-cell research and prevented the previous NIH interpretation from
taking effect. The change in leadership at the DHHS will also ensure
that any decision made on the issue of embryonic stem-cell research
will align with President Bush's agenda as outlined in the Bush
Compromise. Although Secretary Thompson holds personal beliefs in
support of federal funding of embryonic stem-cell research without
restrictions,93 his loyalty to the President is unwavering 94 and will
doubtfully have any influence on DHHS or NIH rulemaking and
interpretation during Bush's tenure in office.
B. NIH Pressed by Current Events
After September 11 th, the issue of stem-cell research in general was
placed on the back burner,95 and the NIH was soon occupied with bio-
terrorism rather than federal research grants. In Congress, the issue
remained alive, but legislators admitted that support for their measures
was weak, especially in the wake of the strong policy statement by
Bush in his compromise plan. 96 In November 2001, Senators dropped
language from a spending bill that would have expanded the sources for
embryos to use in research beyond the standards set by Bush.97 But
despite the current lack of political support, Congress has the power to
change administrative agency rules by passing new standards for
embryonic stem-cell research, and sending the NIH back to the drawing
board. However, if the changes in the Bush Compromise follow the
path of those currently suggested and expand the availability of
embryonic stem-cells for research, the NIH would most likely keep
their current standards and merely expand the opportunities available to
93. Greenberg, supra note 56.
94. Interview, supra note 72.
95. Senate Subcommittee Approves Federal Funding for Stem-Cell Research,
Dow JONES BUSINESS NEWS, Oct. 10, 2001.
96. Id.
97. Alan Fram, Facing Veto Threat, Senators Drop Effort to Ease Bush
Restrictions on Stem Cell Research, ASSOCIATED PRESS NEWSWIRES, Nov. 2, 2001.
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researchers, using the Embryonic Stem-Cell Registry. In this case, the
NIH would continue to operate with the new guidelines for embryonic
stem-cell research without interruption, and could possibly increase
their funding as more opportunities become available. In early 2002,
Congress had all but forgotten the embryonic stem-cell issue, taking up
human embryonic cloning instead.98 However, Congress may have
new ammunition to delve back into the issue after a recent vote by the
German Parliament on embryonic stem-cell research.99 Although the
German Parliament approved restrictions more narrow than those in the
United States, Congress may see this vote as an example of the proper
role for a legislative body.
In addition, Congress must also continue to face the risk of a
national "brain drain" of prominent biomedical researchers as a result
of more permissive laws in other countries, including Canada and Great
Britain. 00 Great Britain, for example, passed a law in 2001 giving
scientists permission to clone human embryos, a move deplored by
most in the United States. 101  In terms of policies on biomedical
research, Sweden, Great Britain, and Canada are considered the most
liberal. 10 2 Researchers hoping to make history on the cutting edge of
biomedical research simply cannot ignore the lure of these countries,
and this fact is likely to influence Congress to act. Perhaps as a hint of
things to come, a Senate Judiciary Committee recently took up a bill by
California Senator Diane Feinstein that would permit cloning of human
embryos for research, but ban cloning to replicate a human.' 0 3 This
98. Edward Epstein, Feinstein Offers Measure to OK Curative Cloning/Senate
Committee Debates Use of Fetal Stem Cells for Research, S.F. CHRON., Feb. 6,
2002, at A3.
99. Fuhrmans & Boston, supra note 20.
100. Akin, supra note 20. The most noteworthy example of a possible trend in
scientists leaving the country is the recent decision by Robert Pedersen, one of the
world's premiere stem cell researchers, who left California last fall to take a job at
the University of Cambridge in England, where he is permitted to clone human
embryos in his stem-cell research. Id. Of course, the one million pound grant
offered to Pedersen probably helped, too. Id.
101. Fuhrmans & Boston, supra note 20.
102. Akin, supra note 20.
103. Epstein, supra note 98. Sure to influence this debate is a report from
scientists in Massachusetts that used cloned cow embryos to create kidney-like
organs that function inside a cow. Rick Weiss, Scientists Claim an Advance in
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indicates that while the particular debate over stem-cell research may
be on hold, the debate over the ethics of embryos is not, and embryonic
stem-cell research is sure to come up again.
However, President Bush's Council announced (only weeks after
formation) that the topic of their first meeting would be human
embryonic cloning, not stem-cell research. 04 Although the meeting did
include a discussion of embryonic stem-cell research, the Council met
primarily to discuss the cloning issue while Congress is simultaneously
debating human cloning. 105
While embryonic stem-cell research has apparently fallen by the
wayside for the time being, the issue has not yet been put to rest by the
media or the public. Critics of embryonic stem-cell research will cite to
the current debate on embryonic human cloning to show that although
the public thought it had reached a reasonable compromise with the
Bush plan, the approval of embryonic stem-cell research only
encouraged the scientific community to push for more egregious,
unethical and immoral research. 106
C. The Bush Compromise: An Exercise in Futility?
The greatest source of discontent with the Bush Compromise is the
belief that Bush did not go far enough-that for adequate research to
exist, many more embryonic stem-cell lines must be derived, and the
restrictions of the Bush Compromise will prevent this from
happening. 107 The challenge to the number of stem-cell lines purported
by the NIH demonstrates this concern, but agency officials are quick to
point out that federally funded research on embryonic stem-cells will
Therapeutic Cloning, WASH. POST, Jan. 30, 2002, at A4. This marks the first use
of cloning technology to grow personalized, genetically matched organs. Id.
104. Across the Nation: Panel Takes on Stem Cell, Cloning Issues, CHI. TRIB.,
Jan. 18, 2002, at 12.
105. Id.
106. This argument tends to fulfill the old adage, "if you give an inch, they'll
take a mile."
107. Senate Subcommittee Approves Federal Funding for Stem-Cell Research,
supra note 95.
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not begin until late 2002,108 so even a valid comparison of the Bush
Compromise to alternative plans suggested by critics will not be
possible until the research has begun. Only then will the diversity of
available stem-cell lines be evaluated properly and compared by
scientists and researchers involved in the actual projects.
In late January 2002, a University of Minnesota research group
confirmed the discovery of "a new and highly versatile class of adult
stem-cell." 10 9  Although no report has yet been published and the
research has yet to be confirmed in other research laboratories, the
potential impact of this news is enormous. If this stem-cell possesses
the pluripotentiality of an embryonic stem-cell and is easily available
and abundant in the body, the need for the embryonic stem-cell will
virtually disappear. A final determination of the impact of these new
cells may not come until 2003, but in the meantime, it could eliminate
the debate over the use of, and need for, embryonic stem-cells at all. In
the big picture, however, the fizzling of the embryonic stem-cell issue
may only give rise to another issue, such as human embryonic cloning,
that will require the same attention and debate. If President Bush
applies the same principles to cloning that he did to embryonic stem-
cell research, it is likely that he, and the NIH, will come out winners.
V. CONCLUSION
Since the discovery of stem-cells in 1998, few question their
potential to provide amazing medical breakthroughs. The unity of the
field of medicine wavers only when the distinction between adult stem-
cells and embryonic stem-cells is made. With clear support for the
research at its most fundamental level, there is little doubt that federal
funding for stem-cell research will continue. Even before the debate
over embryonic stem-cells began, the NIH was already spending $250
million annually on adult stem-cell research, which has continued
unabated during the current controversy. But a resolution of the debate
over federal funding could last years, considering the implications to
108. Interview, supra note 72.
109. Adult Stem Cell Discovery Stirring Up Embryo Debate, Hous. CHRON.,
Jan. 25, 2002, at A12.
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the abortion movement and public policy surrounding the legal status of
unborn children, a controversy that has yet to be resolved.
Federal funding for embryonic stem-cell research was not
scheduled to be approved and distributed until late 2002.' ° The policy
on federal funding could dramatically change through action by
Congress or the President, but is not likely to with the current focus on
the war on terrorism and Iraq. The conclusion, for the time being, is
that President Bush has exerted significant control over NIH policy and
has eliminated the interpretive power of that agency over federal
funding for embryonic stem-cell research. Bush has appropriately
exerted authority over an administrative agency in interpreting and
carrying out federal law, but the question remains as to whether Bush
can implement a policy that is not legislative but rather executive in
origin.
One thing certain to any observer of biotechnology is that advances
in research and technology often require regulatory oversight,
legislative limitations, and accountability. Even more certain, however,
is that biotechnology has, and always will, outpace regulatory policy,
no matter how farsighted the goal. The law is a reactionary institution
by nature, and the NIH embodies this nature by only now attempting to
fund embryonic stem-cell research that has taken place for over five
years. The conflicts between the Bush Compromise and Congressional
interests also highlight the difficulties faced by the NIH in attempting to
promote medical advances and appropriately limit research under the
authority of a conflicted federal government. The Bush Compromise
challenged the NIH in a policy area with a torrid history of conflict, but
through the development of new guidelines and detailed interpretations,
the NIH developed a policy that abides by the Bush Compromise and
promotes medical research that will lead America in the Twenty-First
Century.
110. Interview, supra note 72.

